Key result
Spironolactone is linked to ~58% fewer AF hospitalizations or cardioversions vs. conventional therapy.
Why the study?
The role of spironolactone, a mineralocorticoid receptor blocker with antifibrotic properties, in atrial fibrillation is unexplored.
Does spironolactone reduce the combined outcome of hospitalization for AF or direct current cardioversion in patients with atrial fibrillation and structural heart disease?
Cohort (n=83)
Does spironolactone reduce the combined outcome of hospitalization for AF or direct current cardioversion in patients with atrial fibrillation and structural heart disease?
Absolute Event Rate: 22% vs 53%
p-value: p=0.027
Spironolactone therapy added to conventional medical therapy is associated with a reduced burden of atrial fibrillation, including fewer AF-related hospitalizations and cardioversions.
No takes yet. Share an insight, caveat, or question.
Spironolactone was associated with fewer AF events in this retrospective cohort; hypothesis-generating and requires randomized confirmation before practice change.
Williams et al. (2011) conducted a cohort in Atrial Fibrillation (n=83). Spironolactone vs. Conventional medical therapy alone was evaluated on Combined primary outcome of hospitalization for AF or direct current cardioversion (DCCV) (p=0.027). Spironolactone therapy was associated with significantly fewer AF-related hospitalizations or direct current cardioversions compared to conventional therapy alone (22% vs 53%, P=0.027).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: